Cyrus Arman is Nimble Therapeutics’ Chief Business Officer and is responsible for leading transactions, finance acquisition, and corporate strategy. Cyrus has over 12 years of experience in corporate, clinical, and commercial strategy for biotechnology companies, including advising C-level management and boards of directors on strategy, transactional opportunities, financing, and risk mitigation.

Cyrus’ most recent experience was as the Vice President of Corporate Development and Strategy at NEUVOGEN, Inc., an early stage immunoncology company, where he was responsible for corporate development, business operations, and corporate strategy functions. Prior to NEUVOGEN, he was a director in Amgen’s Corporate Strategy group, prior to that, he rebuilt and ran Amgen’s Global Competitive Intelligence and Strategy unit. Before Amgen, Cyrus was in management consulting where he advised clients in completing complex strategic projects involving multi-billion-dollar business development investments and partnerships in both the Biopharma and Diagnostics sectors.

Cyrus has an MBA from the University of California Los Angeles, a PhD in Neuroscience and an MS in Biomedical Engineering from the University of Southern California, and a BS in Biopsychology from the University of California San Diego.